Replies to post #741 on Oxford BioMedica PLC (OXBDF)

[marcusl2]

Yes well done.

ReNeuron will also receive tiered royalties at rates between 12% and 14% on sales of the licensed products in the Chinese market.

I can see OXB at least doubling in value within a year.